Alterity Therapeutics (ASX:ATH) has announced that the last patient in its ATH434-201 Phase 2 trial in early-stage multiple system atrophy has completed the study. …
Alterity Therapeutics completes last patient visit in ATH434-201 trial in multiple system atrophy
December 4, 2024 Australian Biotech
Latest Video
New Stories
-
ChatGPT would have produced more human responses than these committees
December 5, 2024 - - Latest News -
Anatara provides irritable bowel syndrome clinical trial update
December 4, 2024 - - Australian Biotech -
Digital health company Adherium secures R&D loan facility
December 4, 2024 - - Australian Biotech -
Australians rank access to affordable healthcare as second most important priority
December 4, 2024 - - Latest News -
London Agency bolsters public affairs team with crossbench experience
December 4, 2024 - - Latest News -
Acrux says US FDA approves its nitroglycerin ointment for moderate to severe pain
December 4, 2024 - - Latest News -
Alterity Therapeutics completes last patient visit in ATH434-201 trial in multiple system atrophy
December 4, 2024 - - Australian Biotech